 |
 |
 |
 |
 |
 |
|
 |
 |
 |
Overview Governance SEC Filings News Releases Events Email Notification Investor Kit Snapshot |
 |
OverviewWelcome to Javelin Pharmaceuticals' Investor Relations. On July 2, 2010, as a result of a short-form merger under Delaware law, Javelin Pharmaceuticals became a wholly owned subsidiary of Hospira, Inc., and shares of Javelin are no longer publicly traded. The historical information provided in this portion of the Javelin website is available over the short term for your convenience. Javelin shareholders with share-related questions may refer to Hospira's website at www.hospirainvestor.com or contact Hospira Investor Relations at http://www.hospira.com/GlobalPages/contactus.aspx. About Javelin Through the application of innovative proprietary technologies, Javelin is developing new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Our drug candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Javelin has three late stage product candidates in development: Dyloject™ (injectable diclofenac), Ereska™ (intranasal ketamine) and Rylomine™ (intranasal morphine). Recent ReleasesEvents12/18/2009 9:00 AM ET 11/10/2009 8:30 AM ET |
|
